| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0008 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0008 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0009 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.001 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.098 | 0.001 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.001 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.092 | 0.001 |